title: Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer.
abstract: It is currently hoped that deaths from extra-uterine high-grade serous cancer (HGSC) will be reduced via opportunistic salpingectomy in healthy women. Accumulated data implicate the fimbria as a site of origin and descriptive molecular pathology and experimental evidence strongly support a serous carcinogenic sequence in the Fallopian tube. Both direct and indirect ('surrogate') precursors suggest that the benign tube undergoes important biological changes after menopause, acquiring abnormalities in gene expression that are often shared with malignancy, including PAX2, ALDH1, LEF1, RCN1, RUNX2, beta-catenin, EZH2, and others. However, the tube can be linked to only some HGSCs, recharging arguments that nearby peritoneum/ovarian surface epithelium (POSE) also hosts progenitors to this malignancy. A major sticking point is the difference in immunophenotype between POSE and Müllerian epithelium, essentially requiring mesothelial to Müllerian differentiation prior to or during malignant transformation to HGSC. However, emerging evidence implicates an embryonic or progenitor phenotype in the adult female genital tract with the capacity to differentiate, normally or during neoplastic transformation. Recently, a putative cell of origin for cervical cancer has been identified in the squamo-columnar (SC) junction, projecting a model whereby Krt7+ embryonic progenitors give rise to immunophenotypically distinct progeny under stromal influences via 'top down' differentiation. Similar differentiation can be seen in the endometrium with a parallel in juxtaposed mesothelial and Müllerian differentiation in the ovary. Abrupt mesothelial-Müllerian transitions remain to be proven, but would explain the rapid evolution, short asymptomatic interval, and absence of a defined epithelial starting point in many HGSCs. Resolving this question will require accurately distinguishing progenitor from progeny tumour cells in HGSC and pinpointing where initial transformation and trans-differentiation occur, whether in the tube or POSE. Both will be critical to expectations from prophylactic salpingectomy and future approaches to pelvic serous cancer prevention.
authors.affiliation: Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Crum
authors.forename: Michael
authors.initials: M
authors.lastname: Herfs
authors.forename: Gang
authors.initials: G
authors.lastname: Ning
authors.forename: Jonathan G
authors.initials: JG
authors.lastname: Bijron
authors.forename: Brooke E
authors.initials: BE
authors.lastname: Howitt
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Jimenez
authors.forename: Suchanan
authors.initials: S
authors.lastname: Hanamornroongruang
authors.forename: Frank D
authors.initials: FD
authors.lastname: McKeon
authors.forename: Wa
authors.initials: W
authors.lastname: Xian
mesh_terms: D002278:Carcinoma in Situ / Q000473:pathology*; D002454:Cell Differentiation; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000473:pathology; D018450:Disease Progression; D019317:Evidence-Based Medicine / Q000379:methods; D005185:Fallopian Tube Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D014411:Neoplastic Stem Cells / Q000473:pathology; D010051:Ovarian Neoplasms / Q000473:pathology*; D011230:Precancerous Conditions / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000473:pathology; D014594:Uterine Neoplasms / Q000473:pathology
keywords: BRCA; Fallopian tube; ovarian cancer; p53; p53 signature; serous cancer; stem cell
references.citation: Carcinogenesis. 2013 May;34(5):1125-33
references.pmid: 23299406
references.citation: Cancer Res. 2010 Jul 1;70(13):5316-25
references.pmid: 20530671
references.citation: Nature. 2013 Mar 14;495(7440):241-5
references.pmid: 23467088
references.citation: Int J Gynecol Pathol. 2013 Jul;32(4):345-52
references.pmid: 23722506
references.citation: J Virol. 2002 Jul;76(14):7040-8
references.pmid: 12072504
references.citation: Gynecol Oncol. 2003 Aug;90(2):491
references.pmid: 12893227
references.citation: Gynecol Oncol. 2008 May;109(2):168-73
references.pmid: 18342932
references.citation: Gynecol Oncol. 2000 Apr;77(1):171-6
references.pmid: 10739707
references.citation: J Pathol. 2010 Jan;220(1):17-23
references.pmid: 19834951
references.citation: Obstet Gynecol. 1957 Nov;10(5):469-81
references.pmid: 13477614
references.citation: Cancer Res. 1998 Aug 1;58(15):3254-8
references.pmid: 9699651
references.citation: Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3921-6
references.pmid: 22331912
references.citation: Histopathology. 1995 Oct;27(4):367-71
references.pmid: 8847068
references.citation: J Natl Cancer Inst. 2010 Jan 6;102(1):26-38
references.pmid: 20042715
references.citation: Lancet Oncol. 2012 Mar;13(3):285-91
references.pmid: 22257524
references.citation: Am J Surg Pathol. 2009 Mar;33(3):376-83
references.pmid: 19011565
references.citation: Oncogene. 2011 Aug 11;30(32):3522-36
references.pmid: 21423204
references.citation: Cell. 2011 Jun 24;145(7):1023-35
references.pmid: 21703447
references.citation: Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10516-21
references.pmid: 22689991
references.citation: J Natl Cancer Inst. 2000 Jun 7;92(11):924-30
references.pmid: 10841828
references.citation: Am J Obstet Gynecol. 1979 Apr 15;133(8):859-67
references.pmid: 434029
references.citation: Am J Surg Pathol. 2007 Feb;31(2):161-9
references.pmid: 17255760
references.citation: Gynecol Oncol. 2013 Jun;129(3):448-51
references.pmid: 23558052
references.citation: Clin Transl Oncol. 2008 Oct;10(10):660-4
references.pmid: 18940747
references.citation: J Oncol. 2010;2010:126295
references.pmid: 20445756
references.citation: Cancer Res. 2001 Jun 1;61(11):4311-4
references.pmid: 11389050
references.citation: Am J Pathol. 1999 Apr;154(4):1009-15
references.pmid: 10233839
references.citation: Arch Pathol Lab Med. 2008 Nov;132(11):1753-60
references.pmid: 18976011
references.citation: J Clin Endocrinol Metab. 1973 May;36(5):999-1008
references.pmid: 4698254
references.citation: Am J Surg Pathol. 2006 Feb;30(2):230-6
references.pmid: 16434898
references.citation: Mod Pathol. 2010 Mar;23(3):404-12
references.pmid: 20062014
references.citation: Am J Pathol. 1998 May;152(5):1313-8
references.pmid: 9588899
references.citation: Int J Cancer. 2013 Aug 1;133(3):730-9
references.pmid: 23364849
references.citation: Cancer. 2000 Jul 15;89(2):383-90
references.pmid: 10918170
references.citation: Am J Surg Pathol. 2010 Mar;34(3):433-43
references.pmid: 20154587
references.citation: Gynecol Oncol. 2008 Sep;110(3):408-17
references.pmid: 18597838
references.citation: PLoS One. 2010 Apr 26;5(4):e10358
references.pmid: 20436685
references.citation: Am J Surg Pathol. 2010 Oct;34(10):1407-16
references.pmid: 20861711
references.citation: Int J Gynecol Pathol. 2012 Mar;31(2):103-10
references.pmid: 22317864
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4160-5
references.pmid: 18757330
references.citation: Cancer Res. 2008 Jul 15;68(14):6014-20
references.pmid: 18632658
references.citation: Mod Pathol. 2012 Dec;25(12):1654-61
references.pmid: 22766793
references.citation: Obstet Gynecol. 1981 Dec;58(6):730-4
references.pmid: 7312239
references.citation: J Pathol. 2013 Feb;229(3):460-8
references.pmid: 23007879
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Int J Gynecol Pathol. 2008 Jan;27(1):1-9
references.pmid: 18156967
references.citation: Hum Pathol. 2005 May;36(5):555-61
references.pmid: 15948123
references.citation: Gynecol Oncol. 2013 Jul;130(1):246-51
references.pmid: 23558054
references.citation: Lancet. 2011 Jan 8;377(9760):127-38
references.pmid: 21183212
references.citation: Cancer. 1984 Jul 1;54(1):1-4
references.pmid: 6539159
references.citation: J Pathol. 2010 Sep;222(1):110-6
references.pmid: 20597068
references.citation: Int J Cancer. 2000 Feb 1;85(3):430-7
references.pmid: 10652437
references.citation: Oncogene. 2010 Feb 25;29(8):1103-13
references.pmid: 19935705
references.citation: Mod Pathol. 2012 Mar;25(3):449-55
references.pmid: 22080059
references.citation: Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77
references.pmid: 22556274
references.citation: Carcinogenesis. 2009 Mar;30(3):423-31
references.pmid: 19126650
references.citation: Gynecol Oncol. 2009 Jul;114(1):18-25
references.pmid: 19375154
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6116-26
references.pmid: 16144910
references.citation: Int J Cancer. 2011 Aug 15;129(4):879-86
references.pmid: 20957631
references.citation: Cancer. 1999 Oct 15;86(8):1544-50
references.pmid: 10526284
references.citation: Gastroenterology. 2012 Jun;142(7):1424-30
references.pmid: 22537611
references.citation: J Pathol. 2007 Jan;211(1):26-35
references.pmid: 17117391
references.citation: Clin Obstet Gynecol. 2012 Mar;55(1):24-35
references.pmid: 22343226
references.citation: Vaccine. 2013 Aug 20;31(37):3811-7
references.pmid: 23777956
references.citation: Fertil Steril. 2008 Nov;90(5):2008.e5-8
references.pmid: 18353321